SGS742: the first GABA(B) receptor antagonist in clinical trials.
Froestl
Wolfgang
W
Neuroscience Research, Novartis Pharma AG, WKL-136.5.25, CH-4002 Basel, Switzerland. wolfgang.froestl@pharma.novartis.com
Gallagher
Michela
M
Jenkins
Helen
H
Madrid
Annette
A
Melcher
Thorsten
T
Teichman
Sam
S
Mondadori
Cesare G
CG
Pearlman
Rodney
R
D000328:Adult; D000368:Aged; D000818:Animals; D003072:Cognition Disorders / Q000188:drug therapy*; D005260:Female; D018756:GABA Antagonists / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use*; D058788:GABA-B Receptor Antagonists; D006801:Humans; D008297:Male; D051379:Mice; D009943:Organophosphorus Compounds / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use*; D051381:Rats
D018756:GABA Antagonists; D058788:GABA-B Receptor Antagonists; D009943:Organophosphorus Compounds; C079148:(3-aminopropyl)(n-butyl)phosphinic acid